HOME >> BIOLOGY >> NEWS
Stem cells provide new tool for studying disease and identifying ALS drugs

NEW YORK April 15, 2007 Results of two studies funded by Project A.L.S. and appearing in today's advance online publication of Nature Neuroscience demonstrate that embryonic stem cells may provide a new tool for studying disease mechanisms and for identifying drugs to slow ALS, also known as Lou Gehrig's disease.

Both studies were completed by researchers participating in an ongoing collaboration with the Project A.L.S./Jenifer Estess Laboratory for Stem Cell Research, the world's first and only privately funded laboratory focused exclusively on stem cells and ALS.

The complementary studies, led by Kevin Eggan, of the Harvard Stem Cell Institute, and Serge Przedborski, of Columbia University Medical Center compellingly demonstrate that embryonic stem cells can be used to create an in vitro model of ALS, a fatal neurodegenerative disease that selectively destroys motor neurons, messenger cells responsible for virtually all voluntary movement.

Until now, scientists have not known whether motor neurons in ALS die because of a problem within the cellor from outside the cell. The study by Eggan's group describes successful use of a novel embryonic stem cell-based model for ALS that will help scientists to answer this and other questions. Utilizing this model both Eggan and Przedborski's groups observed that non-neuronal cells called astrocytes may have a toxic effect on motor neurons in ALS.

The Columbia study provides further evidence that astrocytes are toxic to motor neurons in ALS. The Columbia team's discovery of astrocyte-toxic mediators provides not only an insight into how the damage associated with ALS occurs, and a potential biomarker for early diagnosis of the disease but also provides a target for potential new therapies aimed at slowing motor neuron degeneration in ALS.

"That's what happens when scientists from major institutions work together toward shared goals. Project A.L.S. prides itself on b
'"/>

Contact: Patricia Harrington
hsprnyc@aol.com
212-581-0407
PROJECT A.L.S.
16-Apr-2007


Page: 1 2

Related biology news :

1. Newly created cancer stem cells could aid breast cancer research
2. ESF EURYI award winner aims to stop cancer cells reading their own DNA
3. OHSU turns mouse into factory for human liver cells
4. UCLA scientists produce functioning neurons from human embryonic stem cells
5. UCF research links proteins, stem cells and potential Alzheimers treatment
6. Teamwork between 2 key proteins necessary for normal development and regulation of red blood cells
7. In a first, Einstein scientists discover the dynamics of transcription in living mammalian cells
8. How cells change the pace of their steps
9. Discredited Korean embryonic stem cells true origins revealed
10. A low expression of MX2 gene exists in the white blood cells of narcoleptics
11. Penn researchers discover pathway that eliminates genetic defects in red blood cells

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... for drugs, biologics, cell and gene therapies, and consumer health products, today announced ... Boston Virtual Conference & Expo, taking place between Aug. 31 – September 4, ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien ... announced that the U.S. Food and Drug Administration (FDA) has approved the company’s ... for the treatment of severe COVID-19. Approval of this IND allows Sentien to ...
(Date:8/21/2020)... ... August 20, 2020 , ... NDA Partners Chairman ... Clinical Operations executive with expertise in clinical trial planning and feasibility, regulatory inspection ... Expert Consultant. Throughout his career, Mr. Movahhed has helped design and manage oncology, ...
Breaking Biology News(10 mins):
(Date:8/12/2020)... ... August 11, 2020 , ... ... making available for free its new white paper – Simulated Transport Methodologies. ... into today’s biologics licensing application (BLA). In response, Modality Solutions shares an ...
(Date:7/31/2020)... ... July 29, 2020 , ... R3 Stem Cell International is now ... With 50 million stem cells total, patients may choose which extremities they would like ... arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, umbilical cord tissue is obtained ...
(Date:7/31/2020)... ... ... eSource has long been touted as the solution to high data management ... reasons it did not take off as quickly as people initially expected, and where ... towards capturing data electronically for clinical trials and then repurposing it for downstream analysis, ...
(Date:7/18/2020)... ... July 16, 2020 , ... “We are thrilled to deliver ... “It’s the only technology of its kind on the market and we were pleased ... the protective capacity of traditional cultured ingredients, creating a natural way to extend the ...
Breaking Biology Technology:
Cached News: